Mechanisms underlying modifications in the severity of audiogenic convulsions.
D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- / Q000494:pharmacology; D000161:Acoustic Stimulation; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003638:Deafness; D003891:Desipramine / Q000494:pharmacology; D005260:Female; D006321:Heart / Q000187:drug effects; D006892:Hydroxydopamines / Q000494:pharmacology; D007538:Isoniazid / Q000494:pharmacology; D008297:Male; D051379:Mice; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D012110:Reserpine / Q000494:pharmacology; D012640:Seizures / Q000139:chemically induced / Q000209:etiology* / Q000378:metabolism
D006892:Hydroxydopamines; D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; D012110:Reserpine; D003891:Desipramine; D007538:Isoniazid; D009638:Norepinephrine